|
|||
Ribavirin 400 MG Oral Tablet 14 Count Dose Pack |
How old is patient? |
Here is the some steps to help you to save money on Ribavirin 400 MG Oral Tablet 14 Count Dose Pack purchase.
Read drug prescription
What is Ribavirin 400 MG Oral Tablet 14 Count Dose Pack
Ribavirin 400 MG Oral Tablet 14 Count Dose Pack is an antiviral medication.Ribavirin 400 MG Oral Tablet 14 Count Dose Pack must be used together with an interferon alfa product to treat chronic hepatitis C.
Ribavirin 400 MG Oral Tablet 14 Count Dose Pack may also be used for purposes not listed in Ribavirin 400 MG Oral Tablet 14 Count Dose Pack guide.
Ribavirin 400 MG Oral Tablet 14 Count Dose Pack side effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.Stop using Ribavirin 400 MG Oral Tablet 14 Count Dose Pack and call your doctor at once if you have a serious side effect such as:
- problems with your vision;
- fever, chills, body aches, flu symptoms;
- severe pain in your upper stomach spreading to your back, nausea and vomiting, fast heart rate;
- stabbing chest pain, wheezing, feeling short of breath;
- severe depression, hallucinations, thoughts of suicide or hurting yourself;
- chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling; or
- pale or yellowed skin, dark colored urine, easy bruising or bleeding, confusion, or unusual weakness.
Less serious side effects may include:
- headache;
- muscle pain;
- dry mouth;
- nausea; vomiting, stomach pain, loss of appetite;
- weight loss;
- feeling tired or irritable;
- anxiety, mood changes; or
- pain, swelling, or irritation where the interferon injection was given.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
See also: Side effects
Ribavirin 400 MG Oral Tablet 14 Count Dose Pack dosing
Usual Adult Dose for Chronic Hepatitis C:
CAPSULES, ORAL SOLUTION:In combination with peginterferon alfa-2b:
Less than 66 kg: 400 mg orally twice a day
66 to 80 kg: 400 mg orally in the morning and 600 mg in the evening
81 to 105 kg: 600 mg orally twice a day
Greater than 105 kg: 600 mg orally in the morning and 800 mg in the evening
Duration of therapy:
-Interferon alpha-naive patients with genotype 1: 48 weeks
-Interferon alpha-naive patients with genotype 2 and 3: 24 weeks
-Retreatment with peginterferon alfa-2b/ribavirin of prior treatment failures: 48 weeks, regardless of HCV genotype
In combination with interferon alfa-2b:
75 kg or less: 400 mg orally in the morning and 600 mg in the evening
Greater than 75 kg: 600 mg orally twice a day
Duration of therapy:
-Interferon alpha-naive patients: 24 to 48 weeks
-Retreatment with interferon alfa-2b/ribavirin in patients who relapse after nonpegylated interferon monotherapy: 24 weeks
Comments:
-The manufacturer's product information for peginterferon alfa-2b or interferon alfa-2b should be consulted.
-Combination therapy with peginterferon alfa-2b is preferred; provides substantially better response rates than combination therapy with interferon alfa-2b.
-Patients with previous nonresponse, previous pegylated interferon treatment, significant bridging fibrosis or cirrhosis, and/or genotype 1 infection are less likely to benefit from retreatment after a failing course of therapy.
Approved indication: In combination with peginterferon alfa-2b or interferon alfa-2b, for treatment of chronic hepatitis C in patients with compensated liver disease
TABLETS:
In combination with peginterferon alfa-2a:
-Genotypes 1 and 4 in patients less than 75 kg: 1000 mg/day orally in 2 divided doses for 48 weeks
-Genotypes 1 and 4 in patients 75 kg or more: 1200 mg/day orally in 2 divided doses for 48 weeks
-Genotypes 2 and 3: 800 mg/day orally in 2 divided doses for 24 weeks
-Genotypes 5 and 6: Insufficient data to make a recommendation
-In patients coinfected with HIV: 800 mg/day orally in 2 divided doses for 48 weeks, regardless of HCV genotype
Comments:
-The manufacturer's product information for peginterferon alfa-2a should be consulted.
Approved indication: In combination with peginterferon alfa-2a, for treatment of patients with chronic hepatitis C who have compensated liver disease and have not been previously treated with interferon alfa
Usual Adult Dose for Respiratory Syncytial Virus:
Case Review: One vial (6 g) dissolved and delivered through a Small Particle Aerosol Generator (SPAG-2) over a continuous 22-hour period, daily for 5 consecutive daysUsual Pediatric Dose for Respiratory Syncytial Virus:
20 mg/mL as the starting solution in the drug reservoir of the SPAG-2 unit, with continuous aerosol administration for 12 to 18 hours per day for 3 to 7 daysComments:
-The operator's manual for the SPAG-2 should be consulted.
-Using 20 mg/mL, the aerosol concentration for a 12-hour delivery period averages 190 mcg/L of air.
-Ribavirin should not be administered simultaneously or combined with any other aerosolized medications.
-Sudden deterioration of respiratory function has been associated with initiation of Ribavirin 400 MG Oral Tablet 14 Count Dose Pack inhalation therapy in infants; careful monitoring of respiratory function during therapy recommended. If initiation of inhaled Ribavirin 400 MG Oral Tablet 14 Count Dose Pack produces sudden deterioration of respiratory function, therapy should be discontinued and restarted only with extreme caution, continuous monitoring, and coadministration of bronchodilators should be considered.
Approved indication: For treatment of hospitalized infants and young children with severe lower respiratory tract infections due to respiratory syncytial virus
Usual Pediatric Dose for Chronic Hepatitis C:
CAPSULES, ORAL SOLUTION:3 years or older:
In combination with peginterferon alfa-2b or interferon alfa-2b: 15 mg/kg orally per day in 2 divided doses
Ribavirin 400 MG Oral Tablet 14 Count Dose Pack dosages according to weight:
Less than 47 kg: 15 mg/kg orally per day in 2 divided doses
47 to 59 kg: 400 mg orally twice a day
60 to 73 kg: 400 mg orally in the morning and 600 mg in the evening
Greater than 73 kg: 600 mg orally twice a day
Duration of therapy:
-Genotype 1: 48 weeks
-Genotypes 2 and 3: 24 weeks
Comments:
-The manufacturer's product information for peginterferon alfa-2b or interferon alfa-2b should be consulted.
-Combination therapy with peginterferon alfa-2b is preferred; provides substantially better response rates than combination therapy with interferon alfa-2b.
-Patients who reach their 18th birthday while receiving peginterferon alfa-2b plus Ribavirin 400 MG Oral Tablet 14 Count Dose Pack should remain on the pediatric dosing regimen.
-Patients with previous nonresponse, previous pegylated interferon treatment, significant bridging fibrosis or cirrhosis, and/or genotype 1 infection are less likely to benefit from retreatment after a failing course of therapy.
Approved indication: In combination with peginterferon alfa-2b or interferon alfa-2b, for treatment of chronic hepatitis C in patients with compensated liver disease
TABLETS:
5 years or older:
In combination with peginterferon alfa-2a:
23 to 33 kg: 200 mg orally twice a day
34 to 46 kg: 200 mg orally in the morning and 400 mg in the evening
47 to 59 kg: 400 mg orally twice a day
60 to 74 kg: 400 mg orally in the morning and 600 mg in the evening
75 kg or more: 600 mg orally twice a day
Duration of therapy:
-Genotype 2 and 3: 24 weeks
-Other genotypes: 48 weeks
Comments:
-The manufacturer's product information for peginterferon alfa-2a should be consulted.
-Patients who reach their 18th birthday while receiving peginterferon alfa-2a plus Ribavirin 400 MG Oral Tablet 14 Count Dose Pack should remain on the pediatric dosing regimen.
Approved indication: In combination with peginterferon alfa-2a, for treatment of patients with chronic hepatitis C who have compensated liver disease and have not been previously treated with interferon alfa
Select the most affordable brand or generic drug
References
- Dailymed."Ribavirin: dailymed provides trustworthy information about marketed drugs in the united states. dailymed is the official provider of fda label information (package inserts).". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
- Dailymed."Moderiba (ribavirin) kit moderiba (ribavirin) tablet, film coated [abbvie inc.]". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
- "Ribavirin". https://pubchem.ncbi.nlm.nih.gov/co... (accessed August 28, 2018).
Ribavirin 400 MG Oral Tablet 14 Count Dose Pack - Frequently asked Questions
Can Ribavirin 400 MG Oral Tablet 14 Count Dose Pack be stopped immediately or do I have to stop the consumption gradually to ween off?
In some cases, it always advisable to stop the intake of some medicines gradually because of the rebound effect of the medicine.
It's wise to get in touch with your doctor as a professional advice is needed in this case regarding your health, medications and further recommendation to give you a stable health condition.
What other drugs will affect Ribavirin 400 MG Oral Tablet 14 Count Dose Pack?
Tell your doctor about all other medicines you use, especially:
-
abacavir (Ziagen);
-
azathiopriine (Azasan, Imuran);
-
lamivudine (Combivir, Epivir, Epzicom, Trizivir);
-
stavudine (Zerit);
-
tenofovir (Viread);
-
zalcitabine (Hivid); or
-
zidovudine (Retrovir, AZT).
This list is not complete and other drugs may interact with Ribavirin 400 MG Oral Tablet 14 Count Dose Pack. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
Who should not take Ribavirin 400 MG Oral Tablet 14 Count Dose Pack?
You should not take Ribavirin 400 MG Oral Tablet 14 Count Dose Pack if you are allergic to it, or if you have:
-
severe liver disease ;
-
autoimmune hepatitis;
-
a hemoglobin disorder such as anemia, thalassemia (Mediterranean anemia), or sickle-cell anemia;
-
if you are also taking didanosine (Videx); or
-
if you are pregnant woman, or a man whose female sexual partner is pregnant.
To make sure you can safely take Ribavirin 400 MG Oral Tablet 14 Count Dose Pack, tell your doctor if you have any of these other conditions:
-
kidney or liver disease (other than hepatitis C);
-
hepatitis B infection;
-
a blood cell disorder such as hemolytic anemia (a lack of red blood cells);
-
human immunodeficiency virus (HIV or AIDS);
-
diabetes;
-
a pancreas disorder;
-
sarcoidosis;
-
breathing problems;
-
a thyroid disorder;
-
new or worsening eye problems (such as retinopathy);
-
a history of heart disease, high blood pressure, or a heart attack;
-
a history of depression or suicide attempt;
-
a history of a liver, kidney, or other organ transplant; or
-
if you have ever received treatment for hepatitis C that did not work well.
This medication can cause birth defects or death in an unborn baby.
-
If you are a woman, do not take Ribavirin 400 MG Oral Tablet 14 Count Dose Pack if you are pregnant. You will need frequent pregnancy tests to make sure you are not pregnant while taking Ribavirin 400 MG Oral Tablet 14 Count Dose Pack.
-
If you are a man, do not take Ribavirin 400 MG Oral Tablet 14 Count Dose Pack if your female sexual partner is pregnant. An unborn baby could also be harmed if a man fathers the child while he is taking Ribavirin 400 MG Oral Tablet 14 Count Dose Pack. Your sexual partner will need frequent pregnancy tests to make sure she is not pregnant while you are taking Ribavirin 400 MG Oral Tablet 14 Count Dose Pack.
-
Use at least two effective forms of birth control while either sexual partner is taking Ribavirin 400 MG Oral Tablet 14 Count Dose Pack, and for at least 6 months after treatment ends.
-
Tell your doctor right away if a pregnancy occurs while either the mother or the father is taking Ribavirin 400 MG Oral Tablet 14 Count Dose Pack.
Your name may need to be listed on a Ribavirin 400 MG Oral Tablet 14 Count Dose Pack pregnancy registry if you become pregnant while you or your male sexual partner are taking this medication or during the 6 months after treatment ends. This is to track the outcome of the pregnancy and to evaluate any effects of Ribavirin 400 MG Oral Tablet 14 Count Dose Pack on the baby.
It is not known whether Ribavirin 400 MG Oral Tablet 14 Count Dose Pack passes into breast milk or if it could harm a nursing baby. You should not breast-feed while you are taking Ribavirin 400 MG Oral Tablet 14 Count Dose Pack.
Ribavirin 400 MG Oral Tablet 14 Count Dose Pack may affect growth in children.
How should I take Ribavirin 400 MG Oral Tablet 14 Count Dose Pack?
Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.
Ribavirin 400 MG Oral Tablet 14 Count Dose Pack is not effective when used alone to treat hepatitis C. It must be used together with an interferon alfa product to treat chronic hepatitis C.
Take this medicine with food.
Measure the liquid form of Ribavirin 400 MG Oral Tablet 14 Count Dose Pack with a special dose-measuring spoon or cup, not a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.
Ribavirin 400 MG Oral Tablet 14 Count Dose Pack may decrease the number of red blood cells in your body. This is called anemia and it can be life-threatening in people who have heart disease or circulation problems. Your blood will need to be tested often. Your vision, liver function, and thyroid function may also need to be tested. Visit your doctor regularly.
Call your doctor at once if you have pale or yellowed skin, dark colored urine, fever, confusion, chest pain, shortness of breath, or weakness. These may be signs of serious anemia.
Use Ribavirin 400 MG Oral Tablet 14 Count Dose Pack regularly to get the most benefit. Get your prescription refilled before you run out of medicine completely.
Drink extra fluids while you are taking Ribavirin 400 MG Oral Tablet 14 Count Dose Pack to keep from getting dehydrated, especially during exercise or in hot weather.
Ribavirin 400 MG Oral Tablet 14 Count Dose Pack can cause dry mouth, which could lead to tooth decay or gum disease. If you vomit while taking Ribavirin 400 MG Oral Tablet 14 Count Dose Pack, rinse your mouth out with water to prevent damage to your teeth or gums. Be sure to have regular dental exams while you are taking this medication.
Store Ribavirin 400 MG Oral Tablet 14 Count Dose Pack tablets and capsules at room temperature away from moisture, heat, and light.
Store Ribavirin 400 MG Oral Tablet 14 Count Dose Pack liquid (oral solution) in the refrigerator. Do not allow it to freeze.
Can Ribavirin 400 MG Oral Tablet 14 Count Dose Pack be taken or consumed while pregnant?
Please visit your doctor for a recommendation as such case requires special attention.
Can Ribavirin 400 MG Oral Tablet 14 Count Dose Pack be taken for nursing mothers or during breastfeeding?
Kindly explain your state and condition to your doctor and seek medical advice from an expert.
Reviews
Following the study conducted by gmedication.com on Ribavirin 400 MG Oral Tablet 14 Count Dose Pack, the result is highlighted below. However, it must be clearly stated that the survey and result is based solely on the perception and impression of visitors and users of the website as well as consumers of Ribavirin 400 MG Oral Tablet 14 Count Dose Pack. We, therefore, urge readers not to base their medical judgment strictly on the result of this study but on test/diagnosis duly conducted by a certified medical practitioners or physician.Patient reports
Patient reported useful
No survey data has been collected yetPatient reported side effects
No survey data has been collected yetPatient reported price estimates
No survey data has been collected yetPatient reported frequency of use
No survey data has been collected yetPatient reported doses
No survey data has been collected yetPatient reported time for results
No survey data has been collected yetPatient reported administration
No survey data has been collected yetPatient reported age
No survey data has been collected yetPatient reviews
There are no reviews yet. Be the first to write one! |
The information was verified by Dr. Vishal Pawar, MD Pharmacology